NASDAQ · Stocky rates: Avoid

ALKS

$49.59 ▼ -0.04% as of 6 Aug, 13:42
26
/ 100
Avoid

What Stocky thinks

Avoid. ALKS trades at 213.8× forward earnings despite a modest 32/100 Growth Compounder Score and weak 20/100 Value rating, offering no margin of safety. While leadership alignment is respectable (68/100), the company faces structural vulnerability: narrow pipeline, heavy reliance on specialty pharma cycles, and limited competitive moat in psychiatry. Valuation leaves no room for execution risk.

Compounder Score
32/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
68/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
0/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
20/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for ALKS:

26
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 26/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

68
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

0
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

ALKS (ALKS) — frequently asked

Is ALKS (ALKS) a good investment right now?

Stocky rates ALKS (ALKS) at 26/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. ALKS trades at 213.8× forward earnings despite a modest 32/100 Growth Compounder Score and weak 20/100 Value rating, offering no margin of safety. While leadership alignment is respectable (68/100), the company faces structural vulne

What is ALKS's Stocky Verdict?

ALKS's current Stocky Verdict is 26/100, placing it in the "Avoid" band. This composite combines a 32/100 Compounder score, 68/100 Leadership, Moat rating, and analyst signal.

Does ALKS have a competitive moat?

Stocky hasn't finalised a Moat Score for ALKS yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is ALKS's leadership aligned with shareholders?

ALKS scores 68/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to ALKS?

ALKS's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to ALKS.

This is just the surface. See the whole picture on ALKS.

Sign up free and unlock the full analysis on ALKS — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering ALKS — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for ALKS.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how ALKS changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to ALKS?" · "Is ALKS overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
26
/ 100 · Avoid

Or jump straight to the interactive dashboard for ALKS in the app.